--Scinai Immunotherapeutics Ltd. today issued the following letter to shareholders from Chief Executive Officer Amir Reichman. Our new agreement with a U.S.- based, Nasdaq-listed biopharmaceutical company includes approximately $5.1 million in committed base service fees, subject to performance and contractual terms. As of October 20, 2026, our Committed...
Scinai Immunotherapeutics stock jumped 27% after securing a $5.1M biopharma manufacturing deal. Details on SCNI's major contract win.
Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares rose 93.3% to $2.03 during Tuesday's pre-market session. The company's market cap stands at $2.6 million. Scinai Immunotherapeutics (NASDAQ:SCNI) stock rose
--Scinai Immunotherapeutics Ltd., a biopharmaceutical company operating a growing contract development and manufacturing organization alongside an immunology-focused therapeutic development platform, today announced that its wholly owned subsidiary, Scinai Biopharma Services Ltd., has entered into a definitive development and clinical...
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company combining innovative immunology therapeutic development with a revenue-generating contract development and manufacturing organization ("CDMO"), today announced a strategic refocusing of its R&D portfolio following the conclusion of its option and license arrangements with PinCell S.r.l. relating to PC111.
Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum
This is the newest page. Registered accounts read further back.